PMID int64 35.7M 36.4M | Title/Abstract stringlengths 22 8.78k | MeshTerms stringlengths 7 101 | SemanticTypes stringlengths 4 64 |
|---|---|---|---|
36,218,116 | effect ultra earli clip surviv neurolog outcom poor grade aneurysm subarachnoid haemorrhag european stroke organis guidelin advis treat aneurysm subarachnoid haemorrhag asah earli possibl howev optimum time along benefici effect controversi therefor aim investig effect ultra earli clip neurolog outcom surviv poor grade aneurysm subarachnoid haemorrhag | D002532;D013345 | T047;T046;T190 |
36,218,115 | comparison long latenc reflex mix nerv silent period respons various hypokinet movement disord long latenc reflex mix nerv silent period respons electrophysiolog method studi sensorimotor function central nervous system aim studi long latenc reflex mix nerv silent period respons differ type hypokinet movement disord order find electrophysiolog landmark distinguish | D019578;D010300;D013494 | T047;T046 |
36,218,114 | assess serum mmp timp level mmp timp ratio migrain patient without aura matrix metalloproteinas mmp enzym respons proteolyt ac tiviti extracellular matrix protein tissu inhibitor metalloproteinas timp endogen inhibitor mmp act basal membran cerebellar epith lium antagon timp mmp timp ratio exhibit net activ mmp enzym thought role migrain physio pathogenesi | D020780;D008881;D019715 | T047;T126;T116;T123 |
36,218,113 | effect rituximab prognosi myasthenia gravi singl center experi turkey manag treatment resist patient myasthenia gravi mg remain import issu studi aim evalu effect rituximab rtx treatment prognosi patient acetylcholin receptor autoantibodi posit achr ab muscl specif kinas autoantibodi posit musk ab seroneg doubl seroposit mg | D016756;D009157 | T121;T047;T116;T129 |
36,218,110 | ultrasound explor muscl characterist chang diabet peripher neuropathi diabet patient use bright mode ultrasound combin shear wave elastographi studi aim detect structur function chang medial head gastrocnemius mg type diabet mellitus tdm patient without diabet peripher neuropathi dpn | D003929;D003924 | T047 |
36,218,108 | evalu anti inflammatori analges effect hertia intermedia boiss kuntz extract hertia intermedia tradit medicin plant balochistan use pain manag stomach problem current research work intend evalu anti inflammatori analges activ crude ethanol extract h intermedia anti inflammatori activ determin carrageenan induc histamin induc rat paw edema rat analges activ determin acet acid induc writh test formalin induc hind paw lick mice tail immers test h intermedia crude ethanol extract show signific p effect carrageenan histamin induc rat paw edema mgkg oral dose signific analges activ comparison standard drug control p conclud h intermedia crude ethanol extract possess signific anti inflammatori analges effect howev studi may carri isol phytochem respons anti inflammatori analges activ | D019659;D006632 | T121;T109;T123;T002 |
36,218,107 | novel approach quantif paclitaxel load ethyl cellulosekollicoat ethylcelluloseeudragit colloid particl uplc pda optim rapid revers phase ultra perform liquid chromatographi uplc pda method develop valid precis accur quantif paclitaxel drug deliveri system chromatograph separ attain l usp column mm isocrat mobil phase compris acetonitril water flow rate mlmin detect execut nm pda detector propos uplc pda method found rapid retent time min select homogen peak sensit limit detect lod gml limit quantif loq gml method show excel linear r rang mgml appli paclitaxel quantif differ formul infer excipi thus propos approach potenti rapid estim drug puriti assay releas profil pharmaceut prepar | D005079;D017239 | T121;T109;T120;T122 |
36,218,106 | assess covid vaccin booster dose accept reluct concern among elder diabet patient pakistan peopl around globe rumor mani thing safeti efficaci initi two dose booster dose covid vaccin eventu affect accept tool avail fight human virus aim current studi evalu accept reluct level among popul specif elder diabet patient cross section studi conduct time period month ie juli septemb item questionnair use assess accept reluct concern covid vaccin booster dose among elder diabet patient item questionnair use assess accept reluct concern covid vaccin booster dose among elder diabet patient total respons collect analyz approxim respond believ need addit inform covid vaccin booster dose ineffect due enough inform potenti side effect vaccin dose around respond show concern safeti efficaci new enough inform vaccin content around respond express robust concern possibl side effect covid vaccin booster dose | D000086382;D000086663;D003920 | T047;T200;T067 |
36,218,105 | phytochem investig biolog work aerial part root trigonella polycerata purpos studi purifi phytoconstitu explor antibacteri antifung phytotox cytotox potenti dichloromethan methanol extract aerial root part trigonella polycerata phytochem studi methanol extract aerial part plant led isol purif seven compound identifi dimethoxycinnamaldehyd trigocoumarin trimethoxycoumarin penduletin hydroxi tetramethoxyflavon trihydroxi dimethoxyflavon hydroxi dimethoxyflavon structur elucid interpret ei ms nmr spectral data plant aerial part methanol extract tpam demonstr higher antibacteri phytotox growth regul gml cytotox activ ld gml methanol root extract tprm high activ bacteria salmonella typhi staphylococcus aureus escherichia coli fungi like candida albican moder activ brine shrimp larva ld gml dichloromethan aerial tpad root tprd extract exhibit signific antibacteri inhibit respect phytotox growth regul gml potenti tpad indic best inhibit fungi aspergillus flavus moder inhibit microsporum cani phytochem biolog work first time report trigonella polycerata | D029910 | T002 |
36,218,104 | meloxicam load hydroxypropyl methylcellulos hpmc microparticul fabric character vivo pharmacokinet assess meloxicam mel oxicam deriv low water solubl use treatment colorect cancer crc cox inhibitor mel load hpmc micro particl fabric use oil oil oo emuls solvent evapor ese method ftir xrd particl size analysi dsc sem vitro dissolut investig util evalu produc micro particl physiochem final rabbit use anim model vivo pharmacokinet studi assess mel concentr plasma rabbit pure mel f f given rabbit singl dose vivo pharmacokinet investig xrd dsc result confirm transform mel crystallin natur amorph state micro particl formul f f particl size determin respect prepar micro particl smooth non porous spheric surfac comparison pure drug f f cumul drug releas respect pure mel f f estim c max valu gml respect mel half life hour rose hour hour f f respect mel f f auc valu gml h respect consid aspect mel load hpmc micro particl may potenti better deliveri control releas drug easili dissolv water could lead improv therapeut efficaci limit side effect | D052246;D014867 | T121;T109;T197 |
36,218,103 | substitut coumarin deriv activ hslv proteas potenti drug target antibacteri activ bacteri hslvu complex consist two differ protein ie hslv proteas hslu atpas function hslvu enzym complex form hslu c termin helix insert caviti locat two adjac hslv monom order alloster activ hslv proteas base essenti role maintain microbi proteostasi well absenc human be consid promis therapeut target design antibacteri agent goal present studi find potenti drug candid could activ hslv proteas produc aberr proteolysi pathogen bacteria deriv substitut coumarin identifi potenti hslv proteas activ base highest dock score ideal interact pattern signific vitro hslv activ potenti ed valu sub micromolar rang ie conform stabil contact hslv dimer activ compound confirm molecular dynam studi correspond admet characterist lead molecul consider demonstr signific non toxic drug like abil research identifi small non peptid hslv proteas activ also improv understand mode action substitut coumarin deriv antibacteri | D001426;D003374;D010450;D010447;D011480 | T116;T121;T109;T126;T123 |
36,218,102 | fast dissolv oral film approach co load deliv atorvastatin ezetimib better therapeut respons atherosclerot patient suffer acut coronari diseas lie high risk life threaten problem curtail use statin eg ezetimib ezt atorvastatin calcium atc studi co load fast dissolv oral film fdof atc ezt hpmc e prepar solvent evapor method prepar fdof evalu physicochem thermal mechan properti vivo anim studi perform albino rat diet induc hyperlipidemia prepar fdof rapid dt sec tdt min vitro drug releas min dsc ftir xrd analysi prepar film chemic compat chemic interact drug excipi found kinet model observ ezt exhibit lowest r valu zero order kinet best fit model first order kinet n korsmey peppa model film n indic fickian type drug diffus group treat market suspens drug fodp compar normal group high fat diet group studi revil combin fdop atcezt signific reduc hyperlipemia compar high fat diet group conclud atc ezt encapsul fodf provid instant drug releas better therapeut outcom | D019161;D006949 | T121;T047;T109;T033 |
36,218,101 | evalu humor immunolog respons newli prepar bovin multidrug resist staphylococcus aureus mastiti vaccin rabbit multi drug resist mdr staphylococcus aureus creat challeng cure cow mastiti result massiv econom loss global necessit adopt prevent control system vaccin plain pmrsav montanid oil adjuv mmrsav aluminum hydroxid adjuv amrsav vaccin prepar use molecular character isol mdr aureus bovin origin immunogen select isol evalu five group rabbit e differ concentr measur gmt via iha serum sampl booster shot group e provok signific higher p antibodi titer peak day cumul mean antibodi titer cmt rabbit highest follow group c b concentr yield maximum antibodi titer use vaccin prepar vaccin evalu differ rabbit group inocul pmrsav mmrsav amrsav placebo serum sampl evalu iha reveal rabbit inject mmrsav produc highest antibodi titer reach peak day slight decreas day follow amrsav pmrsav challeng protect assay reveal surviv rate rabbit group pmrsav mmrsav amrsav placebo respect studi conclud mmsav amsav safe efficaci immunogen experiment rabbit | D008414;D055624;D013203;D014612 | T047;T116;T007;T121;T129 |
36,218,100 | physicochem rheolog antifung evalu miconazol nitrat organogel topic deliveri topic prepar problem wipe short time result low activ activ moieti research topic organogel og prepar differ oil control action miconazol nitrat various oil check gel form abil control releas og prepar concentr glyceryl monostear differenti scan calorimetri perform studi thermal behavior gel x ray diffract reveal drug chang amorph form crystallin form absenc interact activ ingredi excipi conclud fourier transform infrar spectroscopi permeabl studi carri cellulos acet membran use franz diffus cell contain phosphat buffer salin ph releas drug follow weibul model frequenc sweep test perform studi rheolog behavior optim formul rheolog reveal true natur formul whether gel viscous fluid imag scan electron microscopi show network form gelat molecul antifung activ check c albican niger best formul made tt conclud og gave control topic antifung action | D000935;D008825 | T121;T109;T195 |
36,218,099 | anti inflammatori analges anti pyret activ fagonia bruguieri dc rat tradit medicin employ plant fagonia bruguieri dc allevi inflamm fever pain goal studi test anti inflammatori analges antipyret properti methanol extract whole plant fagonia bruguieri f bruguieri writh test eddi hot plate test use assess analges potenti f bruguieri three differ dose carrageenan induc rat paw edema appli investig anti inflammatori activ wherea antipyret activ estim brewer yeast induc pyrexia model flavonoid alkaloid saponin tannin glycosid found f bruguieri phytochem analysi f bruguieri mgkg reduc writh count percent f bruguieri enhanc latenc eddi hot plate test carrageenan induc edema f bruguieri mgkg exhibit consider anti inflammatori effect percent nd rd th hour therapi f bruguieri also found show antipyret properti anti inflammatori analges antipyret properti f bruguieri confirm studi might attribut presenc sever phyto constitu | D058633;D012503;D028461 | T121;T002;T109;T039 |
36,218,098 | pharmacolog effect gastrointestin respiratori vascular calligonum polygonoid anim model base studi aim studi analyz gastrointestin respiratori vascular pharmacolog effect hydro alcohol extract calligonum polygonoid cp cr anim model procedur carri per previous literatur slight modif necessari found cp cr affect signific relax spontan k mm induc contract result show correspond shift calcium concentr respons curv similar cp cr show relax effect trachea carbachol cch induc tracheal contract moreov contract induc phenylephrin quarantin rabbit aortic prepar caus cp cr induc relax aortal contract verapamil use standard calcium channel blocker find studi suggest vasodil bronchodil spasmolyt effect cp cr | D010276;D019664 | T121;T002;T039 |
36,218,097 | phytochem enzymat biolog studi root extract farsetia hamiltonii royl farsetia hamiltonii royl medicin plant cholistan desert pakistan tradit use treat diabet oxid stress arthriti fever gastrointestin respiratori diseas studi repres unpreced phytochem enzymat biolog properti f hamiltonii root extract prove floric use evalu phytochem constitu done screen total flavonoid phenol content gas chromatographi mass spectrometri phytochem screen reveal presenc glycosid bound anthraquinon flavonoid saponin steroid coumarin diterpen root extract eight compound identifi dichloromethan extract wherea one compound identifi methanol extract root part f hamiltonii dichloromethan extract possess signific lipoxygenas chymotripsin cholinesteras enzym inhibit activ wherea methanol extract possess lipoxygenas alpha glucosidas chymotrypsin acetylcholinesteras enzym inhibit activ antibacteri activ methanol extract signific select five microbi strain nine compound report root part f hamiltonii first time enzym inhibit assay anti cholinesteras anti alpha glucosidas antilipoxygenas antichymotripsin antibacteri activ found signific extract root part f hamiltonii therefor result studi justifi folklor therapeut potenti f hamiltonii root treat diabet inflamm infecti diseas | D019607;D012503 | T109;T002 |
36,218,096 | design synthesi adm biolog evalu molecular dynam studi natur synthet remedi herp simplex virus type garlic known allium sativum one wide use medicin plant world allicin major agent garlic give known pharmacolog activ anti inflammatori antibacteri antifung antivir antioxid agent could extract bulb allium sativum water extract give allicin low yield therefor better method follow extract ultrason assist method give good yield attempt optim allicin extract found slice garlic c minut extract maximum yield gml allicin subject evalu anti herpet herp simplex virus hsv exhibit promis activ compar acyclovir use refer standard hand novel synthet amantadin deriv evalu antiherpet agent prepar reaction thiouracil sulphonyl chlorid amantadin hydrochlorid pyridin synergest effect allicin amantadin deriv evalu hsv use silico molecular dock dynam simul thymidin kinas target enzym chosen analyz possibl interact well protein ligand stabil furthermor properti potenti hsv thymidin kinas target inhibitor amantadin deriv analyz | D005737;D018259 | T168;T005 |
36,218,095 | evalu pyrus communi cydonia oblonga fruit extract load emulgel skin plianci use cutomet current studi design determin skin elast potenti test emulgel formul one emulgel contain pyrus communi fruit extract cydonia oblonga fruit extract purpos femal subject select divid two batch batch volunt use test formul base day skin elast observ use cutomet mpa cutomet skin mechan paramet calcul result note emulgel formul contain extract pyrus communi cydonia oblonga show mark effect facial skin mechan properti day studi period statist observ skin mechan paramet test formul signific differ base distent cutomet formul enhanc retract abil skin compar base moreov also note cydonia oblonga pronounc result pyrus communi load emulgel result interpret although formul good potenti hydrat skin result intensif elast fruit rich sourc phytonutri like vitamin c sugar organ acid might reason enhanc potenti skin plianci | D031989;D027824 | T168;T002 |
36,218,094 | effect combin drug therapi cesarean section prevent postpartum hemorrhag women hypertens disord complic pregnanc studi carri observ effect combin drug therapi cesarean section prevent postpartum hemorrhag women hypertens disord complic pregnanc hdcp women treat hospit hdcp enrol random divid observ group sublingu administr carboprost combin oxytocin treatment iu oxytocin small pot drip iu oxytocin deliveri control group mg carboprost fetal head came appli intramuscular inject iu oxytocin contain comparison postpartum hemorrhag situat two group carri compar control group observ group signific lower intraop blood loss postop h blood loss pthe combin drug therapi cesarean section effect reliabl prevent postpartum hemorrhag women hdcp | D002260;D006473 | T121;T109;T046 |
36,218,093 | interfer morintid virul determin select bacteri pathogen studi small antimicrobi peptid kda amp moringa oleifera l separ crude protein ultra centrifug filter devic partial purifi potenc morintid interfer virul determin like biofilm siderophor elastas select bacteria investig spectrophotometr method pseudomona quinolon signal pqs thin layer chromatographi tlc graphpad prism use statist purpos assay subject two way analysi varianc bonferroni post test shigella flexneri klebsiella pneumonia escherichia coli staphylococcus aureus show decreas attach cell form biofilm presenc morintid pseudomona aeruginosa salmonella typhi show increas attach cell form biofilm morintid effect disrupt develop biofilm case aureus e coli k pneumonia surgic wound flexneri other remain ineffect disrupt develop biofilm siderophor product decreas bacteri strain investig presenc morintid except p aeruginosa outcom research may signific contribut drug discoveri antibiot resist biofilm bacteria | D017262;D013211 | T007;T109;T123 |
36,218,083 | scalabl two tier protrud micro nano optoelectrod array hybrid optic electr modal hierarch modular design situ spatiotempor character correl bioelectr biochem process live multicellular system remain formid challeng offer crucial opportun biolog medicin promis approach develop bio interfac multifunct micro nano sensor array complementari biophoton bioelectron modal biomimet topolog achiev combin bioelectr biochem detect tight devic cell coupl howev system level engin strategi still miss creat multifunct micro nano sensor array meet multifacet design requir situ spatiotempor character live system demonstr hierarch modular design fabric approach develop scalabl two tier protrud micro nano optoelectrod array extend design space biomimet micro nano pillar topolog plasmon nanoantenna base biophoton function surfac enhanc raman spectroscopi ser micro nano electrod base bioelectron function electrochem imped spectroscopi ei notabl two tier protrud micro nano optoelectrod array compos nanolamin nanoantenna array top micropillar electrod array support plasmon nanocav mode high ser enhanc factor larg surfac volum ratio signific reduc interfaci imped ei measur envis scalabl two tier protrud micro nano optoelectrod array potenti serv bio interfac multifunct micro nano sensor array situ correl spatiotempor bioelectr biochem measur live multicellular system neuron network cultur cancer organoid microbi biofilm | D013059;D058266 | T059;T070 |
36,218,074 | bio print photocrosslink anatom tooth shape scaffold alveolar ridg preserv tooth extract alveolar ridg preserv techniqu develop possibl method maintain optimum ridg contour dimens graft bone substitut paramount prevent alveolar ridg resorpt tooth extract howev remain great challeng develop alveolar ridg preserv materi suffici mechan strength bioactiv osteoinduct favor tooth extract socket morpholog match work novel photocrosslink composit ink consist nacr polyurethan pu polyhedr oligomer silsesquioxan poss prepar use fabric porous scaffold alveolar ridg preserv nacrepuposs npp composit character term rheolog behavior mechan properti surfac hydrophil biominer npp scaffold confirm via vitro experi mct e cell distribut homogen npp scaffold stimul cellular prolifer npp scaffold graft socket extract mandibular incisor height width alveolar bone resorpt reduc new bone format observ npp composit promis scaffold materi alveolar ridg preserv print bone graft futur | D000540;D018786;D060734;D016301 | T061;T047;T109;T122 |
36,218,073 | high select chromogen fluorogen chemodosimet dual detect cu base redox activ calix aren isoxazolylchloroanthracen calix aren two lower rim isoxazolylchloroanthracen group shown chromogen also fluorogen chemodosimet select sens cu bind properti ligand control compound toward metal ion ch cnchcl vv investig uv vis fluoresc spectroscopi result show ligand high select cu ion complex cu ligand display new absorpt band around nm color solut chang colorless yellow furthermor fluoresc ligand sever quench cu limit detect lod determin therefor compound chromogen also fluorogen sensor detect cu ion metal ion examin complex ligand cu reduc cu free phenol oh ligand concurr phenol oxid cu quinon h nmr epr ftir spectra provid evid redox behavior ligand cu isol calix diquinon cu ch cn clo reaction ligand cu clo confirm redox reaction | D047250 | T121;T109 |
36,218,069 | par restrict expans neural precursor cell regul hedgehog signal brain develop neural precursor cell npcs expand initi switch generat stage specif neuron maintain self renew abil npc pool onset neurogenesi crucial affect final number type neuron tight regul necessari transit time expans neurogen phase cell howev molecular mechan under transit poor understood report telencephalon specif loss par start neurogenesi lead increas npc prolifer expens neurogenesi result disorgan tissu architectur npcs demonstr hyperactiv hedgehog signal smoothen depend manner well defect primari cilia furthermor loss par enhanc ligand independ ciliari accumul smoothen inhibitor smoothen amelior hyperprolifer npcs telencephalon thus find support idea par crucial role transit npcs expans phase neurogen phase restrict hedgehog signal establish ciliari integr | D053823;D058953 | T025;T123;T116 |
36,218,065 | emerg degrad technolog engag lysosom pathway target protein degrad tpd provid unpreced opportun drug discoveri proteolysi target chimera protac technolog alreadi enter clinic trial chang landscap small molecul drug new degrad technolog har altern degrad machineri especi lysosom pathway emerg broaden spectrum degrad target recent propos concept autophagi tether compound attec hijack autophagi protein microtubul associ protein ab light chain lc target degrad group also report degrad technolog engag lysosom pathway differ mechan includ autac autotac lytac mode review analys discuss attec along lysosom relev degrad technolog final briefli summar current status degrad technolog envis possibl futur studi | D055808;D011506 | T062;T123;T116 |
36,218,061 | depth correct nanosim imag show intracellular lipid cholesterol distribut captur effect differenti sputter rate knowledg distribut drug metabolit drug carrier within cell prerequisit develop effect diseas treatment intracellular compon distribut may imag high sensit spatial resolut use nanosim depth profil mode depth correct strategi captur effect differenti sputter without requir addit measur could enabl produc accur nanosim depth profil imag intracellular compon distribut describ approach depth correct nanosim depth profil imag cell account differenti sputter rate approach use secondari ion secondari electron depth profil imag reconstruct cell morpholog everi raster plane cell morpholog reconstruct use adjust z posit height voxel compon specif nanosim imag valid strategi use afm topographi data reconstruct creat depth profil imag acquir focus ion beam secondari electron microscopi good agreement found shape relat height reconstruct morpholog applic depth correct strategi nanosim depth profil imag metabol label cell better resolv transport vesicl organell organellar membran contain cholesterol n sphingolipid accur nanosim imag intracellular compon distribut may produc without requir correl analys separ instrument assumpt constant sputter rate allow visual subcellular distribut lipid metabolit drug nanoparticl inform pivot understand treat diseas | D018629;D021621 | T059;T062;T073;T060 |
36,218,057 | amyloid tau induc neurotox suppress manuka honey via hsp skn nrf pathway vivo model alzheim diseas alzheim chronic degen diseas central nervous system consid lead caus dementia world character two etiopatholog event relat oxid stress aggreg amyloid peptid format neurofibrillari tangl hyperphosphoryl tau protein brain incid diseas increas age associ inadequ lifestyl natur compound shown improv hallmark diseas howev despit potenti scientif evid manuka honey mh regard present work evalu effect mh toxic induc aggreg tau caenorhabd elegan model result demonstr mh abl improv indic oxid stress delay induc paralysi ad model cl hsp skn nrf pathway nevertheless sugar content impair indic locomot indic tau neurotox transgen strain br wild type n worm | D000544;D006722;D029742 | T047;T168;T116;T048 |
36,218,054 | immun senesc periodont mechan therapi periodont one preval infecti inflammatori diseas character irrevers destruct support tissu teeth correl greater risk multipl system diseas thus regard major health concern dysregul periodont microbi communiti host immun consid lead caus periodont comprehens studi unveil doubl edg role immun respons develop periodont immun senesc describ age relat alter immun system includ diminish immun respons endogen exogen stimuli declin effici immun protect even failur immun build vaccin lead increas suscept infect recent intim relationship immun senesc periodont come focus especi age popul review periodont immun immun senesc fulli introduc especi role patholog progress periodont furthermor novel immunotherapi target immun senesc present provid potenti target research clinic intervent futur | D010518 | T047 |
36,218,053 | modul gut microbiota hypoglycemichypolipidem activ flavonoid fruit lycium barbarum high fat dietstreptozotocin induc type diabet mice lycium barbarum use tradit medicin edibl plant china fruit l barbarum rich flavonoid larg explor potenti associ antioxid anti inflammatori activ may contribut reduc risk diabet howev inform antidiabet activ flavonoid l barbarum lbfs still limit studi therefor effect lbfs high fat diet hfd streptozotocin stz induc type diabet tdm mice investig lbfs show signific anti diabet activ evidenc recoveri various physic sign bodi weight level glp increas water consumpt liver index fast blood glucos homa ir homa level hbac ogtt decreas improv function glucos lipid metabol level tc tg serum liver decreas mrna express gk pfk ppar increas mrna express gpase pepck ppar fas acc srebp c inhibit reduct express proinflammatori cytokin relat mrna lps tlr tnf il il ifn restor liver tissu structur character reduct fat vesicl remiss hepatocyt swell order arrang hepat cord moreov modul gut microbiota hfdstz induc tdm mice explor result show bacteroidaless group lachnospiracea ruminococcacea clostridialesvadinbbgroup allobaculum turicibact coriobacteriaecea enterococcus domin bacteria associ tdm conclus lbfs amelior hfdstz induc tdm mice three target includ improv glucos lipid metabol block pro inflammatori cytokin regul gut microbiota except optim dose lbfs need explor | D032305;D003924;D003921;D000069196 | T050;T047;T002;T007;T001 |
36,218,050 | spier memori lectur challeng cryo electron microscopi articl provid introductori background overview discuss meet begin account key mileston develop cryo em field follow overview present form basi discuss | D020285 | T059 |
36,218,040 | hollow microneedl array fabric use ration design prevent skin clog transderm drug deliveri microneedl mn technolog promis replac hypoderm needl practic use painless drug deliveri howev complex top fabric process function mn array bottleneck hinder widespread use fabric taper hollow mn array use uniqu bi level tip combin strain engin capillari self assembl carbon nanotub cnt microstructur strain engin facilit offset pattern catalyst enabl growth bent bi level cnt microstructur capillari self assembl help constitut taper geometri mns bottom fabric consist two standard photolithographi step cnt growth form scaffold mns follow polym polyimid reinforc step impart mechan stiff mns provid scalabl fewer process step taper shape mn allow time smaller forc pierc penetr skin compar straight mn liquid deliveri rate bi level tip mn measur better flat tip mn lumen size geometri reduc skin clog effect needl tip addit cytotox test verifi polyimid reinforc cnt mns biocompat futur vivo applic | D037742 | T104;T073 |
36,218,039 | freez trigger gelat quatern chitosan reinforc microfibril cellulos high effici remov bilirubin high effici remov bilirubin blood hemoperfus liver failur therapi remain challeng clinic field due low adsorpt capac poor hemocompat current use carbon base adsorb polysaccharid base cryogel seem promis candid hemoperfus adsorb owe inherit excel hemocompat howev weak mechan strength relat low adsorpt capac polysaccharid base cryogel limit applic bilirubin adsorpt work present freez trigger strategi fabric qcsmfc cryogel form quatern chitosan qcs crosslink divinylsulfonyl methan bvsm reinforc microfibril cellulos mfc ice crystal exclus trigger chemic crosslink generat cryogel dens pore wall obtain qcsmfc cryogel character ftir sem stress strain test hemocompat assay exhibit interconnect macropor structur excel shape recoveri mechan perform outstand blood compat due quaternari ammonium function chitosan qcsmfc show high adsorpt capac mg g short adsorpt equilibrium time h import qcsmfc still exhibit high adsorpt effici presenc g l albumin furthermor qcsmfc could also maintain high dynam adsorpt effici self made hemoperfus devic facil approach provid new avenu develop high perform hemoperfus adsorb bilirubin remov show great promis translat therapi hyperbilirubinemia | D048271 | T121;T109 |
36,218,036 | network model activ elast shell swollen hydrostat pressur mani organ elast skeleton consist close shell epitheli cell fill fluid activ regul elast forc shell hydrostat pressur insid work introduc simpl network model pressur stabil activ elast shell cross link repres materi point connect non linear spring given equilibrium length spring constant mimic activ contractil forc system chang paramet random chosen spring use comput simul studi result local global deform dynam network elucid statist properti deform comput correspond distribut correl function show pressur induc stretch network introduc coupl local global behavior network oppos contract excit spring affect amplitud relax time deform random local excit give rise contract network fluctuat surfac area | D006874 | T070 |
36,218,033 | condit null allel dynch enabl target analys dynein role neuron length sens size homeostasi fundament process biolog particular import larg cell neuron previous propos motor depend length sens mechan wherein reduct microtubul motor level would expect acceler neuron growth valid predict dynein heavi chain loa mutant dynchloa sensori neuron describ new mous model condit delet allel exon dynch homozyg islet cre mediat delet dynch isl dynch delet protein motor sensori neuron embryon lethal heterozyg anim isl dynch surviv adulthood dynein express target cell isl dynch sensori neuron reveal acceler growth previous report dynchloa neuron moreov isl dynch mice show mild impair gait propriocept tactil sensat similar seen dynchloa mice confirm specif aspect loa phenotyp due reduc dynein level isl dynch mice also show delay recoveri peripher nerv injuri like due reduc injuri signal deliveri axon lesion site thus condit delet dynch exon enabl target studi role dynein neuron growth | D004398;D056445 | T126;T123;T116 |
36,218,031 | effect neutral antibodi sotrovimab among high risk patient mild moder sar cov qatar estim real world effect sotrovimab sever critic fatal covid qatar time sar cov incid occur due ba omicron subvari | D000086402;D000086382 | T067;T047;T005 |
36,218,024 | accumul galactinol aba involv exogen ebr induc drought toler tea plant drought stress sever limit growth caus loss yield tea plant exogen applic epibrassinolid ebr posit regul drought respons various plant howev whether ebr could contribut drought resist tea plant under mechan investig found ebr applic benefici drought toler tea plant transcriptom result reveal ebr could contribut tea plant drought resist promot galactinol abscis acid aba biosynthesi gene express content galactinol elev ebr ebr respons csdof posit regul express galactinol synthas gene csgol csgol contribut accumul galactinol direct bind promot moreov exogen ebr found elev express gene relat aba signal transduct stomat closur regul result promot stomat closur addit ebr respons csmyc involv aba accumul bind promot csnced csnced activ express summari find studi provid knowledg transcript regulatori mechan ebr induc drought resist tea plant | D055864;D028241 | T002;T070 |
36,218,021 | dispatch biotech begin beginng rapid newborn genom sequenc end diagnost therapeut odyssey dispatch biotech briefli review urgent need extens expans newborn screen nbs genom sequenc reason earli attempt limit success next decad transform develop continu societi pharmaceut biotechnolog informat medic sector enabl prompt addit genet disord nbs rapid whole genom sequenc rwgs upon introduct new therapi qualifi accord wilson jungner criteria wilson j g jungner g world health organ principl practic screen diseas world health organ retriev https appswhointirishandl herein describ plan progress clinic trial design beginng newborn genom sequenc end diagnost therapeut odyssey new intern pre competit public privat consortium propos implement self learn healthcar deliveri system screen newborn hundr genet diseas diagnost confirm implement effect treatment acceler orphan drug develop invit investig stakehold worldwid join consortium prospect multi center intern trial clinic util cost effect beginng | D015997;D001709 | T061;T091 |
36,218,012 | associ urinari polycycl aromat hydrocarbon metabolit symptom among autist children case control studi tianjin china polycycl aromat hydrocarbon pah ubiquit pollut associ alter neurodevelop various neurodevelopment disord howev studi evalu intern biomark pah exposur refer sever autism spectrum disord asd symptomolog autist behavior scarc henc conduct case control studi evalu urinari hydroxyl pah metabolit ie hydroxi pah children autism neurotyp children match accord sex age ratio children asd sever symptomolog autist behavior assess use child autism rate scale car autism behavior checklist abc found urinari level nine hydroxi pah statist signific higher asd group except hydroxynaphthalen ohnap hydroxyphenanthren ohph moreov urinari hydroxi pah level associ asd risk odd ratio rang exposur hydroxynaphthalen ohnap hydroxyphenanthren ohph hydroxypyren oh pyr hydroxybenzofuran ohdbf oh pah posit associ car score adjust covari p appli abc scale ohpyr level posit associ abc total score strongest associ evidenc regard social related languag domain p bayesian kernel machin regress bkmr show consist posit exposur respons ohnap ohph ohph level regard car score ohpyr level regard abc total score find suggest children asd may higher urinari level hydroxi pah biomark level associ increas odd asd increas sever autism symptomolog increas autist behavior children autism lay summari conduct epidemiolog studi evalu associ urinari hydroxi pah level autism spectrum disord asd autism symptomolog autist behavior found urinari hydroxi pah statist signific associ asd note strong statist signific associ ohnap ohph ohph level increas sever autism symptomolog well strong statist signific associ ohpyr level behavior characterist within social linguist domain work confirm contribut futur develop diagnost children mild autism well environment measur promot health wellb children autism spectrum disord | D000067877;D001321;D004785;D011084 | T109;T131;T048 |
36,218,011 | onlin administr ado research adolesc adult respons pandem studi evalu onlin ado modul administr adolesc adult n femal without n femal histori autism spectrum disord asd complet ado modul via videoconfer parent caregiv complet parentcaregiv form vineland adapt behavior scale achenbach adult behavior checklist ado review score five train clinician supervis senior clinician establish research reliabl autist group score differ ado total calibr sever score wps instrument domain score ksad domain score achenbach score inter rater reliabl moder percentag item wise agreement r onlin ado show signific converg parent report assess asd relev symptom characterist suggest valid assess onlin assess must use caution result suggest approach describ could suffici valid reliabl fill urgent need assess evalu asd symptomatolog one compon thorough clinic evalu asd relat behavior lay summari exploratori studi ask whether possibl give ado adolesc adult complet onlin way result show expert clinician agre ado item also particip autism higher score part ado onlin ado score strong signific relationship parent report friendship social skill need research test method way ado onlin may use clinician research urgent need evalu autism pandem | D000067877;D001321 | T048 |
36,217,998 | progress australian journal rural health celebr thirtieth anniversari thirti year ago first edit australian journal rural health ajrh publish follow review publish time review progress made bring improv health outcom resid rural remot australia past decad compound covid crisi affect health health care system throughout australia review note signific lack progress past decad amelior ongo problem poor access primari health care associ avoid hospitalis persist poor health indigen australian greater preval rang health risk factor follow find recent new south wale enquiri rural health review highlight need implement mani recommend emerg wealth evid base research publish journal ajrh improv health outcom increas pariti equiti health metropolitan non metropolitan australian | D000086382;D019035 | T047;T093;T073;T058;T067 |
36,217,985 | frailti prefrailti peopl live hiv focus women live hiv increas lifespan peopl live hiv plwh frailti prefrailti becom topic requir attent reciproc interact chronic inflamm comorbid frailti demonstr complex pathophysiolog frailti consequ femal sex hiv infect without antiretrovir treatment reduc cd cell count depress cardiovascular diseas risk factor frailti among plwh frailti predispos fall therefor lead frequent fractur hospit death especi women osteoporosi continu antiretrovir treatment prevent comorbid depress diagnosi prefrailti crucial intervent slow develop frailti review summar literatur frailti peopl live hiv discuss frailti manag strategi order improv health outcom women live hiv | D000073496;D015658 | T047;T046;T184;T033 |
36,217,966 | ferrocen potenti electrochem report surrog abas site dna method real time monitor substrat accept modifi nucleotid dna polymeras high demand step toward aim incorpor ferrocen base abas nucleotid dna templat evalu compat enzymat synthesi unmodifi modifi dna canon nucleotid incorpor opposit ferrocen site strong prefer purin dna polymeras lesion bypass capac dpo allow dna synthesi resum beyond site incorpor modifi purin nucleotid readili incorpor opposit ferrocen basic site analog pyrimidin nucleotid decor simpl side chain also readili toler find open direct design electrochem sens devic monitor enzymat synthesi natur modifi dna | D004259;D004247 | T126;T116;T123;T114 |
36,217,963 | lesson earli life understand develop expand stem cell treat cancer haematopoiet stem cell hsc self renew process essenti develop homeostasi blood system self renew expans divis creat two daughter hscs singl parent hsc har creat larg number hscs wide rang cell gene therapi process also driver abnorm expans hscs diseas cancer although hscs first produc earli embryon develop key stage locat undergo maxim expans foetal liver make tissu rich sourc data deciph molecul drive hsc self renew anoth equal interest stage occur post birth sever week hscs migrat bone marrow hscs undergo development switch adopt dormant state characteris transit point develop key understand evolut haematolog malign develop method promot hsc expans spotlight articl provid overview key insight studi hsc develop brought field hsc expans translat medicin mani set stage next big breakthrough field | D006412;D009369 | T191;T025 |
36,217,958 | metallacarboran deriv innov anti candida albican agent infect caus candida speci increas signific past decad among lead caus morbid mortal worldwid result serious public health problem current convent antifung often ineffect candida spp develop grow resist system drug sinc inorgan metallacarboran known affect cellular event new deriv abiot compound test candida albican compound base cobalt bis dicarbollid cosan studi candida albican strain includ panel clinic isol present data prove metallacarboran deriv effect clinic isol candida albican even resist system drug show synergist potenti combin amphotericin b low toxic human cell danio rerio embryo paper consequenti step investig broad spectrum valuabl futur medic applic metallacarboran especi fight drug resist pathogen | D002176;D000935 | T121;T004;T195 |
36,217,946 | oral intervent narirutin amelior allerg respons ovalbumin allergi new intervent investig induct oral toler ot ova use narirutin vivo vitro experi combin network pharmacolog structur analysi molecular dock narirutin metabol naringenin effect ot affect b cell function dcs cell respons predict verifi narirutin could affect b cell function secret antibodi therebi reduc abil dcs absorb antigen affect gata ccr stat mhcii express regul cell respons suppress th improv treg cell vivo molecular dock show steric hindranc effect may reason weaker bind energi target narirutin howev mean bioactiv inhibit mast cell degranul find interest offer possibl use natur compound promot oral toler | D050799;D006967 | T046;T123;T116 |
36,217,933 | descript basic compet clinic ultrasound imag emerg depart recent year seen great advanc use clinic ultrasound imag hospit emerg depart hospit set howev new techniqu requir date definit compet relev clinic realiti differ specialti geograph set specialist work end group expert clinic ultrasound review evid avail literatur strict appli delphi method defin compet relev emerg physician group work start premis clinic ultrasound imag common compet across specialti | D002983;D004636 | T093;T073;T080 |
36,217,932 | qualiti hospit emerg depart care patient covid first wave calur covid studi defin qualiti care indic care process standard treat patient covid hospit emerg depart ed determin level adher standard first wave detect factor associ differ level adher | D000086382 | T047;T067 |
36,217,931 | deriv valid new prehospit phenotyp adult covid character phenotyp prehospit patient covid facilit earli identif risk group | D000086382;D004632 | T047;T093;T061;T058;T067 |
36,217,930 | differ clinic sign sever intox due street drug adolesc young adult treat emerg depart determin whether symptom level sever intox street drug differ adolesc young adult come hospit emerg depart treatment | D002188;D003042;D013287;D007649;D012978 | T002;T167;T131;T121;T109 |
36,217,929 | emerg depart observ patient acut heart failur prior hospit admiss impact short term prognosi analyz whether short term outcom affect patient diagnos acut heart failur ahf spend time emerg depart observ unit edou hospit admiss | D004636;D006333 | T093;T046;T073;T047 |
36,217,928 | safeti ketamin reduc fractur pediatr emerg depart ketamin one wide use drug analgesia sedat reduc fractur pediatr emerg depart ed aim analyz safeti intraven iv ketamin administ physician anesthesiologist | D050723;D007649 | T121;T109;T037 |
36,217,927 | associ blood pressur vasopressor wean hospit surviv analysi vasopressor target analyz associ blood pressur vasopressor wean hospit mortal patient admit intens care unit icu | D006973 | T047 |
36,217,917 | role scamp central nervous system diseas secretori carrier membran protein scamp constitut group membran transport protein plant insect mammal mammalian genom contain five type scamp gene name scamp scamp scamp particip vesicl cycl fusion vesicl cell membran play role regul exocytosi endocytosi activ synapt function transmit nerv signal among protein scamp high express brain direct indirect effect function central nervous system paper may allow us better understand role scamp central nervous system diseas scamp regul membran transport control exocytosi svs relat secret carrier membran function addit scamp play major role normal mainten physiolog function nerv cell articl summar effect scamp nerv cell exocytosi endocytosi synapt function well relationship scamp various neurolog diseas better understand role scamp pathogenesi neurolog diseas | D002352;D008565 | T123;T116;T192 |
36,217,911 | radiat treatment respons hypoxia biomark reveal machin learn assist raman spectroscopi tumour cell xenograft tissu recent advanc anatom imag tumour treatment target led improv rt howev unlik improv anatom imag alon sole driver new advanc personalis rt biochem base radiobiolog inform like requir next generat improv personalis radiotherapi dose prescript individu patient paper use raman spectroscopi rs optic techniqu monitor individu biochem respons radiat within tumour microenviron spatial correl individu biochem respons augment deriv hypox map within tumour microenviron furthermor pair rs data analyt framework combin group basi restrict non negat matrix factor gbr nmf ii random forest rf classifi iii featur metric import calcul method shapley addit explan shap order ascertain relat import individu biochem describ overal biolog respons observ rs current studi found gbr nmf rf shap model help identifi wide rang radiat respons biomark hypoxia indic eg glycogen lipid dna amino acid h human lung cancer cell h xenograft correl hypox region raman chemic biomark eg glycogen alanin arginin also identifi h xenograft summar gbr nmf rf shap combin rs appli monitor rt induc biochem respons within cellular tissu environ individu biochem identifi contribut overal biolog respons radiat ii spatial correl hypox region tumour rs combin analyt pipelin show promis understand individu biochem dynam radiat respons use cancer therapi | D013059;D000860 | T046;T059;T070;T184;T033 |
36,217,909 | facil access difluoro dihydrofuran skeleton without extra addit dmf promot difluorocarben format clcf co na practic facil difluorocarben trigger cycloaddit reaction enaminon develop deliv difluoro dihydrofuran broad substrat scope notabl reaction proceed smooth without extra addit readili avail sodium chlorodifluoroacet clcf co na scda serv difluorocarben precursor transform dmf promot moreov prove difluoro dihydrofuran deriv exhibit potenti antiprolif activ human tumour cell hela mcf hepg | D012964;D012863 | T034;T022;T123;T196 |
36,217,898 | synthesi h indolo indol one via palladium catalyz c h bond activ difluorocarben transfer pd catalyz annul iodophenyl h indol sodium difluorochloroacet develop synthes h indolo indol one deriv via c h bond activ difluorocarben transfer rout enabl facil access target product various substitu moder high yield method featur high reactiv good function group toler simpl oper procedur mild reaction condit reaction carri gram scale | D010165;D007211 | T109;T196 |
36,217,894 | caregiv engag pediatr post acut care hospit caregiv engag acut inpati hospit demonstr provid development behavior benefit children decreas readmiss length stay improv caregiv confid caregiv engag examin acut care set howev gap inform regard caregiv engag pediatr post acut care hospit ppach object studi explor caregiv engag ppach | D017028;D019467 | T098;T097;T099;T091 |
36,217,888 | atherosclerot cardiovascular risk emerg prioriti pediatr last decad childhood adolesc emerg import window opportun prevent atherosclerot cardiovascular diseas ascvd later life discuss under advanc field first atherosclerosi develop start earli childhood atherogenesi initi iliac arteri abdomin aorta subsequ develop higher region arteri tree demonstr nonhuman primat studi human autopsi studi obes hypertens hyperlipidemia hyperglycemia young age acceler atherogenesi children adolesc obes relat risk ascvd mortal later life compar peer normal weight convers earli prevent improv long term cardiovascular outcom second review diseas associ factor add tradit risk factor various pediatr disord carri similar even higher risk ascvd obes includ chronic inflammatori disord organ transplant recipi famili hypercholesterolemia endocrin disord childhood cancer survivor chronic kidney diseas congenit heart diseas prematur birth especi fetal growth restrict involv diseas associ factor fuel atherogenesi divers includ inflamm vascular endotheli factor divers grow list pediatr group risk underscor cardiovascular risk manag solid enter realm general pediatr second review seri therefor focus recent advanc cardiovascular risk assess manag implic pediatr practic | D002318;D050197;D010372 | T091;T047;T046 |
36,217,886 | increas cytotox ru ii polypyridyl complex tune electron donat abil phenanthrolin ligand ruthenium ru base chemotherapeut agent choic replac tradit platinum contain metallodrug due fewer side effect prove mechan ru complex drug high like bind dna certain protein also high depend electron structur ru complex howev relationship electron properti chemotherapeut activ yet complet system investig limit effect drug design strategi herein propos increas electron densiti ru would enhanc nucleophil substitut rate chlorin atom cl ru provid better bioactiv amino acid nucleic acid seri complex various optim electron donat group edg synthes accord dft calcul addit kinet substitut l histidin dna bind experi cell cytotox studi verifi assumpt surpris complex could also potenti cellular imag probe via unpreced light switch mechan live cell caus homo lumo distribut chang ru complex interact dna accord reactiv select demonstr compound support develop ru complex cancer treatment afford strateg perspect develop metal complex chemotherapeut agent bioimag probe | D012428;D056831;D000970 | T121;T104;T196;T109 |
36,217,884 | mechanist insight borrow hydrogen n alkyl catalyz mlc catalyst dual proton respons site metal ligand cooper mlc catalysi one import concept field organometal catalysi howev divers function ligand result ambigu mechan constrain understand mlc catalysi herein theoret studi base dft calcul perform shed light mechanist prefer borrow hydrogen n alkyl catalys ruthenium complex dual proton respons site result suggest reaction pathway mediat nh site requir overcom higher activ energi barrier kcal mol compar nh site due ligand distort proton nevertheless instabl caus ligand distort transform catalyt activ subsequ hydrogen reaction contrast nh site facilit rate determin hydrid transfer step kcal mol via non coval interact instead particip bond format break process found plausibl mechan find demonstr versatil role ligand n h function may provid use guidanc design new mlc catalyst futur | D011522;D006859 | T196 |
36,217,883 | stepwis structur evolut cluster base framework silver cluster pair chiral framework r ag ag orang fluoresc success synthes transform thermodynam favor denser stack r ag ag accompani chang luminesc activ cpl signal captur structur determin intermedi r ag ag reveal coordin instabl na ion main caus transit | D012834;D049449 | T196;T070 |
36,217,876 | direct transfer consolid synthet yeast chromosom abort mate chromosom elimin larg dna transfer technolog challeng rapid develop larg dna assembl technolog research applic synthet yeast chromosom most limit assembl host mutant kar prevent nuclear fusion yeast mate occasion singl chromosom transfer one parent nucleus anoth use kar mutant method four synthet yeast chromosom sc syniii synv synx synxii transfer wild type yeast separ syniii also transfer industri strain result improv thermotoler moreov combin abort mate chromosom elimin crispr cas report previous studi develop strategi consolid multipl synthet yeast chromosom compar previous pyramid strategi use endoredupl backcross method linear process independ meiosi provid conveni path acceler consolid sc chromosom overal method transfer consolid synthet yeast chromosom abort mate chromosom elimin enabl novel rout larg dna assembl donor yeast vivo direct transfer receptor yeast enrich manipul tool synthet genom | D012441;D002875 | T026;T004 |
36,217,874 | pharmacist led medic therapi manag diabet club patient primari healthcar clinic cape town south africa retrospect prospect audit diabet mellitus dm complex chronic condit remain public health concern worldwid south africa sa mani patient dm access public sector primari healthcar clinic consid stabl refer club system manag multidisciplinari team patient dm often diagnos concurr medic condit result multipl medic therapi lead medic therapi problem mtps prescrib adher standard treatment guidelin stgs aim improv glycaem control minimis complic decreas healthcar cost pharmacist role medic therapi manag mtm dm underutilis public sector healthcar facil object evalu implement pharmacist led mtm intervent optimis manag stabl patient type dm attend diabet club cape town communiti day centr method evalu studi design use case studi approach conduct month novemb june retrospect prospect audit conduct patient folder stabl patient attend club quantit data extract folder train pharmacist audit baselin pre intervent data prescrib staff notifi therapeut discrep written pharmacist pharmacotherapeut recommend intervent pharmacist led intervent audit prescrib adher sa stgs essenti medicin list prescrib respons pharmacist recommend post intervent record accept partial accept reject estim cost calcul ration irrat prescrib aspirin mtm process result patient folder audit femal n total mtps identifi averag four intervent per folder review common mtps identifi absenc basic clinic data bodi mass index document folder medic indic note laboratori test request clinician prescrib accept pharmacist recommend found low suggest clinic inertia aspirin found irrate prescrib patient dm conclus pharmacist identifi resolv prevent mtps rationalis appropri medic therapi patient dm prescrib uptak pharmacist pharmacotherapeut recommend seem overlook pharmacist led workshop advoc ration prescrib need mitig mtps among stabl patient type dm public sector healthcar facil | D003924;D010595 | T047;T097 |
36,217,873 | diagnost perform dobutamin stress echocardiographi south african experi dobutamin stress echocardiographi dse well establish modal diagnosi coronari arteri diseas report diagnost data southern africa object compar safeti sensit specif south african sa dse programm larger intern seri method patient undergo dse singl sa centr includ new wall motion abnorm segment signifi induc ischaemia result total patient mean standard deviat age year male analys six patient experienc chest pain dse develop atrial arrhythmia sensit specif epicardi coronari stenosi respect chang exclud previous coronari arteri bypass surgeri conclus sensit specif safeti sa dse programm compar intern seri dse programm feasibl resourc constrain environ | D004280;D025401 | T121;T109;T060 |
36,217,872 | safeti efficaci inclisiran south african patient high cardiovascular risk subanalysi orion phase iii clinic trial inclisiran signific reduc low densiti lipoprotein cholesterol ldl c individu heterozyg famili hypercholesterolaemia establish atherosclerot cardiovascular diseas ascvd ascvd risk equival type diabet famili hypercholesterolaemia year risk cardiovascular event orion phase iii clinic trial infrequ dose day result mean ldl c reduct total particip south africa sa enrol local data need support use inclisiran sa popul potenti address unmet need addit ldl c lower therapi object analys orion phase iii trial data assess efficaci safeti inclisiran sa particip method orion randomis doubl blind phase iii trial particip receiv maxim toler statin without lipid lower therapi exclud protein convertas subtilisinkexin type pcsk inhibitor particip randomis inclisiran sodium mg mg free acid placebo administ day co primari endpoint ldl c percentag chang baselin day time averag percentag chang ldl c baselin day day key secondari endpoint includ absolut chang ldl c baselin day time averag absolut chang baselin day day chang lipid lipoprotein result mean age particip year male mean ldl c level baselin mmoll day inclisiran reduc ldl c level compar placebo confid interv ci p lt correspond time averag reduct ldl c ci p lt treatment emerg advers event inject site common inclisiran compar placebo v howev mild moder natur none persist conclus inclisiran given addit maxim toler standard lipid lower therapi effect safe result robust reduct ldl c sa patient high cardiovascular risk | D050197;D002318;D003924;D019161;D006938 | T121;T047;T046;T109 |
36,217,871 | solid malign first year life year review red cross war memori children hospit cape town south africa among paediatr tumour two group stand neonat infantil tumour respect repres paediatr tumour distribut tumour age group differ older children object descript analysi cohort patient treat solid malign red cross war memori children hospit rcwmch cape town south africa method year retrospect case seri review patient age lt year diagnosi perform data extract rcwmch oncolog databas result case extract databas solid tumour includ analysi exclud benign eye bone central nervous system origin therefor meet inclus criteria renal malign neuroblastoma soft tissu sarcoma germ cell tumoursgonad tumour liver tumour patient surgeri chemotherapi radiotherapi tumour group year surviv neuroblast tumour nephroblastoma hepatoblastoma rhabdomyosarcoma non rhabdomyosarcoma soft tissu sarcoma respect malign extracrani extragonad germ cell tumour entir cohort mean follow month estim year overal surviv mortal loss follow conclus distribut tumour differ slight literatur predomin renal tumour neuroblastoma overal mortal rate surgic complic rate year overal surviv correspond literatur support view paediatr hospit middl incom countri achiev result similar higher incom countri intern protocol appli dedic multidisciplinari team | D009373;D009447;D012509 | T191 |
36,217,870 | immunolog virolog outcom children lamivudin monotherapi south african public sector experi resourc limit set hold regimen lamivudin monotherapi lam use manag hiv posit children fail combin antiretrovir therapi mitig risk drug resist develop adher barrier address access second third line regimen restrict south african hiv treatment guidelin previous advoc use lam manag hiv infect children virolog failur howev outcom patient lam compar continu fail regimen well describ object investig characterist larg cohort children place lam outcom method retrospect review children virolog failur document mv drug resist mutat place lam v control group children continu fail regimen despit persist virolog failur virolog immunolog outcom lam compar patient remain fail regimen result total children includ analysi lam group control group median interquartil rang iqr age baselin year median cd count cellsl median hiv viral load iqr log twenti two children lam group control group experienc immunolog deterior statist differ two group regard overal time immunolog deterior log rank p valu conclus given higher proport children lam group experienc immunolog failur lam strategi may use short term one restrict children limit treatment option manag children virolog failur continu challeng improv adher strategi avail | D019380;D015658 | T121;T047 |
36,217,869 | open ident gamet donat law south africa south african sa gamet bank gamet donat agenc offer open ident donor general believ donor anonym legal requir sa howev analysi sa statutori instrument case law show belief mistaken gamet donat sa anywher spectrum anonym known accord open ident gamet donat would law sa offer public sa gamet bank gamet donat agenc | D018587;D014019 | T098;T061 |
36,217,868 | prophylaxi new standard care patient haemophilia randomis control clinic trial evid prophylaxi optim care patient haemophilia generat decad ago howev knowledg translat clinic practic south africa sa owe mani barrier prophylaxi includ high treatment burden impos prophylaxi frequent inject two four time week need intraven access administ replac clot factor therapi higher volum clot factor requir compar episod treatment recent introduc non factor therapi haemophilia care address mani barrier exampl emicizumab current global approv non factor therapi administ subcutan less frequent week fortnight everi week led global adopt prophylaxi standard care haemophilia bleed disord communiti haemophilia preval clot factor defici sa gt peopl diagnos date howev patient current prophylaxi practic articl review rational prophylaxi outlin goal benefit provid evid base guidanc haemophilia patient prioritis emicizumab prophylaxi consensus guidanc facilit adopt prophylaxi nation polici new standard care haemophilia sa | D006467 | T047 |
36,217,867 | persist matern tachycardia clinic alert healthcar profession provid matern care south africa cardiac diseas one commonest caus indirect matern death global brief report remind isol matern tachycardia rest clinic alert warrant detail histori relat cardiac disord thorough clinic examin organ system relev investig imag expert advic avoid serious advers event reflect belat investig persist matern tachycardia result fatal postpartum collaps due mitral stenosi lost window opportun appropri investig manag tachycardia provid insight mani similar matern death south africa key clinic messag regard persist matern tachycardia present midwiv doctor care pregnant women | D063130;D008427 | T058;T040 |
36,217,861 | nonspecif deidentif date like text deidentifi clinic note enabl reidentif date facilit secondari usag electron health record data research univers california san francisco ucsf recent implement clinic data warehous includ among data deidentifi clinic note report avail ucsf research without institut review board approv deidentif note health insur portabl account act identifi redact date transform shift date patient back random number day describ issu nonspecif ie excess transform nondat date like text deidentif process enabl reidentif date includ birthdat certain patient issu undercut common assumpt excess deidentif safe tradeoff protect patient privaci present issu caution institut may also consid releas deidentifi note research | D000068240;D060145 | T170;T066;T052 |
36,217,860 | matern mental health caregiv compet hiv posit negat women care singleton newborn kwazulu natal provinc south africa matern mental health perinat period interest mani research antenat depress postnat depress pnd lead caus morbid advers effect matern depress offspr throughout infanc childhood adolesc well document studi mental health person live hiv also report high preval depress | D019052;D015658 | T047;T048 |
36,217,859 | treat urinari tract infect public sector primari healthcar facil cape town south africa pharmaceut perspect antibiot resist global healthcar burden complic manag infect urinari tract infect uti common treat primari care manag uti appropri primari care combat antibiot resist treatment practic uti primari care western cape provinc south africa well describ | D009582;D014552 | T121;T047;T109;T195 |
36,217,858 | phase diavacc screen trial studi design method popul demograph baselin result human papillomavirus hpv base primari screen guidelin base screen test perform preval data generat high resourc area low hiv infect rate urgent need local data infect diseas preval well screen test perform among hiv posit hiv negat south african sa women order inform updat screen guidelin object studi describ baselin characterist particip cross section phase multicentr diagnosi vaccin cervic cancer screen diavacc screen trial object determin preval posit screen pre invas diseas use differ test strategi sa hiv posit hiv negat popul | D015658;D030361;D002583;D014612 | T047;T116;T191;T121;T129 |
36,217,857 | bleed thrombosi outcom hospitalis covid patient low molecular weight heparin antiplatelet therapi increas incid thromboembol event hospitalis covid patient demonstr despit use low molecular weight heparin lmwh antiplatelet therapi prior admiss earli diseas cours hypothesis protect thrombosi | D000086382;D013927 | T047;T046;T067 |
36,217,856 | non fatal injuri among boy girl present red cross war memori children hospit cape town south africa south africa sa road traffic injuri homicid burn lead caus injuri relat death among children injuri relat death well document sa case non fatal injuri | D002056;D014947 | T037 |
36,217,855 | themat analysi challeng option portfolio committe health review nation health insur bill portfolio committe health pch obtain public input nation health insur bill wide array individu organis may septemb record submiss collat parliamentari monitor group provid sourc materi articl concern suggest issu rais respond analys determin challeng option pch need take serious prepar bill parliament promin issu rais includ concern propos govern structur flaw fund model risk corrupt constitut human right risk limit access care sever group unresolv natur medic benefit provid bill futur legal contest bill sever issu potenti stop delay implement long time pch hard decis make whether address concern quit radic revis bill omit problemat element leav unchang accept contest bring | D006806;D009313 | T064;T058;T078;T170;T089 |
36,217,853 | cost harm alcohol use south africa repli murray barr letter matzopoulo et al articl murray barr murray barr gdi cost harm alcohol use south africa commentari afr med j https doiorgsamjvi | D000437 | T048 |
36,217,846 | drug pharmacokinet obes popul challeng common assumpt predictor obes relat paramet chang obes associ mani physiolog chang review avail evid regard five common accept assumpt priori predict impact obes drug pharmacokinet pk | D009765;D010599 | T047;T062;T039 |
36,217,844 | evalu sotorasib treatment patient non small cell lung cancer krasgc mutat improv clinic outcom patient krasgc mutat non small cell lung cancer nsclc major current former smoker barrier improv popul level outcom nsclc novel effect krasgc inhibitor emerg sotorasib first member class achiev commerci avail | D002289;D008175 | T191 |
36,217,841 | sickl cell diseas gulf cooper council countri systemat review evid relat nation burden sickl cell diseas scd gulf cooper council gcc larg fragment thus aim studi system review studi gcc countri assess epidemiolog profil scd | D000755;D006453 | T047 |
36,217,840 | advanc antifoul antibacteri hydrogel enabl control thermo respons biocompat polym composit optim appli antibiot antimicrobi smart wound dress confer control drug releas prevent adhes biolog object advantag poli n isopropylacrylamid pnipaam convent thermo respons polym poli methacryloyloxyethyl phosphorylcholin pmpc typic antifoul polym therefor potenti fabric copolym achiev dual function thermo respons antifoul herein hydrogel made pnipam co pmpc design load octenidin wide appli antimicrobi agent wound treatment achiev antifoul trigger drug releas thermo switch fabric hydrogel allow fold octenidin releas c infect wound temperatur c normal skin temperatur minut led least lg reduct viabl bacteria c artifici infect wound furthermor pioneer assess antifoul properti materi pbs buffer use singl moleculecellbacteri forc spectroscopi reveal fabric hydrogel display distinct antifoul properti protein mammalian cell bacteria work demonstr promis design hydrogel applic prevent treat wound infect concept dual function materi envisag clinic applic relat prevent biofilm associ infect urinari cathet stent dental implant | D057219;D015921 | T074;T070 |
36,217,833 | socio cognit analysi farmer water conserv behaviour case kavar plain iran agricultur activ lot effect environ water conserv measur help produc crop consum water resourc sustain present research main aim explor farmer water conserv behaviour use comprehens action determin model cadm research conduct farmer kavar plain far provinc iran n sampl includ farmer taken stratifi random sampl techniqu measur instrument questionnair whose face content valid confirm panel expert check reliabl pilot studi conduct calcul cronbach alpha composit reliabl cr result show indic use measur research variabl proper fit factor structur theoret framework studi base result social norm person norm attitud object constraint subject constraint affect farmer water conserv intent posit signific also farmer behaviour influenc intent well subject object constraint conclud farmer water conserv behavior shape process involv normat process habitu process situat attitud | D000074067;D000067565 | T057;T097 |
36,217,831 | rate rare copi number variant differ circumst among patient genet development epilept encephalopathi patient development epilept encephalopathi dee genet etiolog uncov differ method although chromosom microarray analysi cma broad use patient dee data still limit | D001927;D056915 | T047;T045;T086 |
36,217,823 | illumin new path multicellular new speci multicellular bacteria broaden understand prokaryot multicellular provid insight multicellular organ aris | D005075 | T045 |
36,217,821 | cannabinoid signal modul jzl restor key phenotyp mous model william beuren syndrom william beuren syndrom wbs rare genet multisystem disord character mild moder intellectu disabl hypersoci phenotyp life threaten featur cardiovascular abnorm nowaday pharmacolog treatment direct amelior main trait wbs endocannabinoid system ec given relev cognit cardiovascular function could potenti druggabl target syndrom analyz compon ec complet delet cd mous model wbs assess impact pharmacolog modul key phenotyp relev wbs cd mice show characterist hypersoci phenotyp prefer social novelti poor short term object recognit perform brain cannabinoid type receptor cbr cd male mice show alter densiti coupl detect chang main endocannabinoid endocannabinoid signal modul subchron day jzl select inhibitor monoacylglycerol lipas specif normal social cognit phenotyp cd mice notabl jzl treatment improv cardiovascular function restor gene express pattern cardiac tissu result reveal modul ec promis novel therapeut approach improv key phenotyp alter wbs | D002186;D018980 | T121;T047;T109 |
36,217,820 | touch sensit stamen enhanc pollen dispers scare away visitor anim pollin plant get pollen conspecif stigma protect get eaten touch sensit stamen found hundr flower plant thought function enhanc pollen export reduc loss experiment test scarc stamen berberi mahonia insert pair nectar gland touch insect tongu rapid snap forward valvat anther press pollen insect tongu face immobil stamen otherwis unmodifi flower studi pollen transfer field enclos condit flower immobil stamen common bee visitor stay longer yet remov fewer pollen grain deposit fewer grain stigma per visit self pollen singl stamen hit stigma amount grain receiv singl bee visit bee discard pollen passiv place bodi like berberin content nectar berberin syrphid fli fed nectar pollen take stamen immobil pollen track experi two berberi speci show mobil stamen flower donat pollen mani recipi result demonstr anoth mechan plant simultan meter pollen reduc pollen theft | D057048;D054817 | T123;T040 |
36,217,819 | singl cell transcript roadmap human pacemak cell differenti heartbeat trigger sinoatri node san primari pacemak heart studi anim model reveal pacemak cell share common progenitor pro epicardium pacemak cardiomyocyt diversifi transit tail head subtyp howev under molecular mechan especi human pacemak cell develop poor understood perform singl cell rna sequenc scrna seq trajectori infer human induc pluripot stem cell hipsc differenti san like cardiomyocyt sancm construct roadmap transcript chang lineag decis differenti sancm identifi distinct cluster close resembl differ subpopul vivo san moreov presenc side popul proepicardi cell suggest share ontogeni sancm also report vivo result demonstr diverg sancm proepicardi lineag determin wnt signal furthermor uncov role tgf wnt signal branch transit head sancm subtyp respect find provid new insight molecular process involv human pacemak cell differenti open new avenu complex diseas model vitro inform approach cell therapi base regener san | D057026 | T025 |
36,217,817 | novel multicellular prokaryot discov next underground stream divers prokaryot current exhibit multicellular differ generat mechan varieti context ecolog earth present studi report new type multicellular bacterium hs isol underground stream hs self organ filament cell layer structur coloni properti nemat liquid crystal matur coloni start form semi close sphere accommod cluster coccobacillus daughter cell select releas upon contact water first report show liquid crystal status cell support prokaryot multicellular behavior import observ behavior hs suggest recurr intermitt exposur coloni water flow cave might ecolog context cultiv evolutionari transit unicellular multicellular life new extant model underpin theori regard role ecolog context emerg multicellular | D005075;D060587 | T082;T045;T081;T070 |
36,217,793 | mcc centrosom protein reloc non centrosom apic site intestin cell differenti gene mutat colorect cancer mcc encod coil coil protein implic name suggest pathogenesi hereditari human colon cancer date howev contribut mcc intestin homeostasi diseas remain unclear examin subcellular local mcc mrna protein level adult intestin epithelium find reveal mcc transcript restrict prolifer crypt cell includ lgr stem cell mcc protein distinct associ centrosom upon intestin cellular differenti mcc redeploy apic domain polar villus cell non centrosom microtubul organ center ncmtoc posit use intestin organoid show shuttl mcc protein depend phosphoryl casein kinas critic modul wnt signal togeth find support role mcc establish maintain cellular architectur intestin epithelium compon centrosom ncmtoc | D022101;D018385 | T026 |
36,217,792 | initi experi brachytherapi treatment adjuv surgic resect keloid scar pediatr popul treatment keloid scar base multipl line therapi vari level efficaci current singl treatment guarante cure prevent recurr pediatr popul treatment use standard insuffici evid support efficaci complic object studi analyz patient requir brachytherapi adjuv surgic resect recurr keloid scar | D001918;D007627 | T061;T020 |
36,217,791 | buri peni secondari ectop scrotum ectop scrotum rare clinic entiti potenti associ congenit abnorm present case patient buri peni secondari ectop scrotum surgic techniqu describ literatur review carri | D019651;D014564 | T061;T019 |
36,217,790 | common surgic train program standard learn qualiti various surgic specialti center use simul experiment surgeri resourc avail train task minim invas surgeri mis individu manner learn model great dispers effort expens observ decid creat unifi program base follow share learn synergi among specialti moder econom cost ration use facil | D007396;D010535 | T061;T065;T097;T060 |
36,217,789 | implement pediatr robot surgeri program futur perspect minim invas approach use robot technolog fulli incorpor treatment adult patholog first intern pediatr studi robot approach date spain present implement pediatr robot surgeri program set | D065287;D012371;D013043 | T091;T061;T090 |
36,217,788 | pop mechan protect factor chronic renal diseas children posterior urethr valv identifi whether pop mechan act protect factor chronic end stage renal diseas patient posterior urethr valv | D007676;D051436;D014524 | T047 |
36,217,787 | congenit malform urinari tract progress chronic renal diseas congenit nephrourolog abnorm cakut particular relev group diseas due high preval fact main caus chronic renal diseas crd pediatr popul object determin characterist preval cakut set identifi factor associ occurr renal damag | D007676;D051436;D014551;D014718 | T047;T023 |
36,217,786 | incident appendectomi surgic treatment ileocol intussuscept children safe perform surgic treatment ileo colic intussuscept ici report second caus emerg laparotomi children perform incident appendectomi surgic reduct current controversi aim analys outcom perform incident appendectomi surgic ici reduct without associ bowel resect | D001064;D013505;D007443;D010535 | T061;T047;T060 |
36,217,785 | postop hyperlipasemia perfor append children object studi assess hyperlipasemia case detect postop period perfor append | D001064;D007415;D010195 | T047;T046 |
36,217,780 | palladium catalyz aminocarbonyl isoquinolin util chloroform cowar chemistri carbonyl group form integr part sever drug molecul materi henc synthesi carbonyl compound remain intrigu area research synthet medicin chemist handl toxic co gas sever limit thus use safe effect techniqu ex situ generat carbon monoxid nontox cheap precursor high desir among sever precursor explor generat co gas chloroform prove promis co surrog due cost effect readi avail howev one pot chloroform base carbonyl reaction requir strong basic condit hydrolysi chloroform may affect function group toler substrat scale reaction limit overcom two chamber reactor cowar util ex situ co generat hydrolysi chloroform one chamber facilit safe carbonyl reaction anoth chamber mild condit versatil chloroform cowar techniqu explor palladium catalyz aminocarbonyl medicin relev heterocycl core viz isoquinolin quinolin | D010165;D002725 | T131;T109;T196;T130 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.